Should we use poor prognosis factors to start early treatment in patients with rheumatoid arthritis?
Lara
L
Valor
Inmaculada
I
de la Torre Ortega
D000942:Antigens, Bacterial / Q000276:immunology; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001323:Autoantibodies / Q000032:analysis / Q000097:blood; D015415:Biomarkers; D002956:Citrulline / Q000032:analysis; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006681:HLA-D Antigens / Q000276:immunology; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D018716:Molecular Mimicry; D010455:Peptides / Q000032:analysis / Q000276:immunology; D016966:Porphyromonas gingivalis / Q000276:immunology; D057285:Precision Medicine; D011379:Prognosis; D011499:Protein Processing, Post-Translational; D054596:Protein Tyrosine Phosphatase, Non-Receptor Type 22 / Q000235:genetics / Q000276:immunology; D012217:Rheumatoid Factor / Q000097:blood; D012307:Risk Factors; D013582:Synovial Fluid / Q000737:chemistry; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000942:Antigens, Bacterial; D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D006681:HLA-D Antigens; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D002956:Citrulline; D012217:Rheumatoid Factor; C516765:PTPN22 protein, human; D054596:Protein Tyrosine Phosphatase, Non-Receptor Type 22; D008727:Methotrexate